Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
M. Erro Iribarren (Madrid, Spain), C. Cisneros Serrano (Madrid, Spain), C. Acosta Gutiérrez (Madrid, Spain), A. Roca Noval (Madrid, Spain), A. Martínez Meca (Madrid, Spain), E. García Castillo (Madrid, Spain), M. Hernández Olivo (Madrid, Spain), J. B Soriano (Madrid, Spain), J. Ancochea Bermúdez (Madrid, Spain)
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Erro Iribarren (Madrid, Spain), C. Cisneros Serrano (Madrid, Spain), C. Acosta Gutiérrez (Madrid, Spain), A. Roca Noval (Madrid, Spain), A. Martínez Meca (Madrid, Spain), E. García Castillo (Madrid, Spain), M. Hernández Olivo (Madrid, Spain), J. B Soriano (Madrid, Spain), J. Ancochea Bermúdez (Madrid, Spain). Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma. 2520
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: